These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1682328)

  • 21. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
    Holtzman JL; Kaihlanen PM; Rider JA; Lewin AJ; Spindler JS; Oberlin JA
    Arch Intern Med; 1988 Mar; 148(3):539-43. PubMed ID: 3277569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    Kirby RS
    Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative trials of terazosin with other antihypertensive agents.
    Ruoff G
    Am J Med; 1986 May; 80(5B):42-8. PubMed ID: 2872806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with terazosin administered in combination with other antihypertensive agents.
    Chrysant SG
    Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of terazosin on blood pressure and serum lipids.
    Gong P; Tang J; Cheng L; Lu Z; Zhang J; Zeng F
    J Tongji Med Univ; 1999; 19(4):291-4. PubMed ID: 12938521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
    Lowe FC; Olson PJ; Padley RJ
    Urology; 1999 Jul; 54(1):81-5. PubMed ID: 10414731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha 2-agonist versus alpha 1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies.
    Harris SI; Alvarez C
    Am J Ther; 1997 Jan; 4(1):9-15. PubMed ID: 10423584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker.
    Abraham PA; Halstenson CE; Matzke GR; Napier JL; Keane WF
    Pharmacotherapy; 1985; 5(5):285-9. PubMed ID: 2866492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
    Achari R; Hosmane B; Linnen P; Cavanaugh J; Baroldi P; Cohen A
    J Clin Pharmacol; 1998 Jun; 38(6):545-53. PubMed ID: 9650545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of terazosin as an antihypertensive agent.
    Luther RR; Glassman HN; Jordan DC; Sperzel WD
    Am J Med; 1986 May; 80(5B):73-6. PubMed ID: 2872811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
    Shionoiri H; Gotoh E; Ito T; Hata T; Iwatsubo H; Takegawa K; Ogihara T; Mikami H; Ikegami H; Otsuka A
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S91-5. PubMed ID: 7908168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.